according to the OSHA Hazard Communication Standard



# Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.1 09/30/2023 7942487-00007 Date of first issue: 03/19/2021

#### **SECTION 1. IDENTIFICATION**

Product name : Oxfendazole / Oxyclozanide Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc Address : 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary medicine Restrictions on use : Not applicable

#### **SECTION 2. HAZARDS IDENTIFICATION**

# GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Combustible dust

Reproductive toxicity : Category 1B

Specific target organ toxicity

- single exposure (Oral)

Category 2 (Central nervous system)

Specific target organ toxicity :

- repeated exposure

Category 2 (Liver, Testis, Brain)

**GHS** label elements

Hazard pictograms



Signal Word : Danger

Hazard Statements : If small particles are generated during further processing, han-

dling or by other means, may form combustible dust concentra-

tions in air.

H360FD May damage fertility. May damage the unborn child. H371 May cause damage to organs (Central nervous system) if

swallowed.

H373 May cause damage to organs (Liver, Testis, Brain)

through prolonged or repeated exposure.

Precautionary Statements : Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

according to the OSHA Hazard Communication Standard



# Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.1 09/30/2023 7942487-00007 Date of first issue: 03/19/2021

and understood.

P260 Do not breathe dust.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product. P280 Wear protective gloves, protective clothing, eye protection

and face protection.

Response:

P308 + P311 IF exposed or concerned: Call a doctor.

P308 + P313 IF exposed or concerned: Get medical attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents and container to an approved waste

disposal plant.

### Other hazards

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

### **SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

### Components

Chemical name	CAS-No.	Concentration (% w/w)	
Oxyclozanide	2277-92-1	48	
oxfendazole	53716-50-0	24	
Starch, oxidized	65996-62-5	16.7216	
Magnesium stearate	557-04-0	1.392	

### **SECTION 4. FIRST AID MEASURES**

General advice : In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

according to the OSHA Hazard Communication Standard



# Oxfendazole / Oxyclozanide Formulation

Version **Revision Date:** SDS Number: Date of last issue: 04/04/2023 09/30/2023 7942487-00007 Date of first issue: 03/19/2021 3.1

Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and

delayed

May damage fertility. May damage the unborn child.

May cause damage to organs if swallowed.

May cause damage to organs through prolonged or repeated

exposure.

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation. Protection of first-aiders First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Treat symptomatically and supportively. Notes to physician

#### **SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media : Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical None known.

Unsuitable extinguishing

media

Specific hazards during fire

fighting

Avoid generating dust; fine dust dispersed in air in sufficient

concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides

Chlorine compounds Nitrogen oxides (NOx)

Metal oxides

Oxides of phosphorus

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment.

Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO

Evacuate area.

Special protective equipment:

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

#### **SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protec- : tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions Avoid release to the environment.

> Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for Sweep up or vacuum up spillage and collect in suitable

according to the OSHA Hazard Communication Standard



# Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.1 09/30/2023 7942487-00007 Date of first issue: 03/19/2021

containment and cleaning up container for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

#### **SECTION 7. HANDLING AND STORAGE**

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe dust. Do not swallow.

Avoid contact with eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Keep container tightly closed.

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labeled containers.

Store locked up. Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

### **SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**

Ingredients with workplace control parameters

according to the OSHA Hazard Communication Standard



# Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.1 09/30/2023 7942487-00007 Date of first issue: 03/19/2021

inert or nuisance dust 50 Million particles per cubic foot

Value type (Form of exposure): TWA (total dust)

Basis: OSHA Z-3

15 mg/m<sup>3</sup>

Value type (Form of exposure): TWA (total dust)

Basis: OSHA Z-3

5 mg/m<sup>3</sup>

Value type (Form of exposure): TWA (respirable fraction)

Basis: OSHA Z-3

15 Million particles per cubic foot

Value type (Form of exposure): TWA (respirable fraction)

Basis: OSHA Z-3

Dust, nuisance dust and par-

ticulates

10 mg/m<sup>3</sup>

Value type (Form of exposure): PEL (Total dust)

Basis: CAL PEL

5 mg/m<sup>3</sup>

Value type (Form of exposure): PEL (respirable dust fraction)

Basis: CAL PEL

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Oxyclozanide	2277-92-1	TWA	0.4 mg/m3 (OEB 2)	Internal
oxfendazole	53716-50-0	TWA	40 μg/m3 (OEB 3)	Internal
		Wipe limit	400 μg/100 cm <sup>2</sup>	Internal
Starch, oxidized	65996-62-5	TWA (inhal- able dust)	0.5 mg/m <sup>3</sup>	ACGIH
Magnesium stearate	557-04-0	TWA (Inhal- able particu- late matter)	10 mg/m³	ACGIH
		TWA (Respirable particulate matter)	3 mg/m³	ACGIH

**Engineering measures** : All engineering controls should be implemented by facility

design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face

containment devices).

Minimize open handling.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to

maintain vapor exposures below recommended limits. Where

according to the OSHA Hazard Communication Standard



# Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.1 09/30/2023 7942487-00007 Date of first issue: 03/19/2021

concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided

by air purifying respirators against exposure to any

hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other

circumstance where air purifying respirators may not provide

adequate protection.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets,

disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures,

industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

#### **SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance : powder

Color : white to off-white, light cream, cream

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling :

range

No data available

according to the OSHA Hazard Communication Standard



# Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.1 09/30/2023 7942487-00007 Date of first issue: 03/19/2021

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing,

handling or other means.

Flammability (liquids) : Not applicable

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : Not applicable

Relative vapor density : Not applicable

Relative density : No data available

Density : 0.88 g/cm<sup>3</sup>

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

#### **SECTION 10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing,

handling or other means.

Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

according to the OSHA Hazard Communication Standard



# Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 09/30/2023 7942487-00007 Date of first issue: 03/19/2021 3.1

Avoid dust formation.

Incompatible materials

Oxidizing agents

Hazardous decomposition

products

No hazardous decomposition products are known.

#### **SECTION 11. TOXICOLOGICAL INFORMATION**

#### Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

### **Acute toxicity**

Not classified based on available information.

#### **Product:**

Acute oral toxicity Acute toxicity estimate: > 5,000 mg/kg

Method: Calculation method

#### Components:

Oxyclozanide:

Acute oral toxicity LD50 (Rat): 3,519 mg/kg

Target Organs: Central nervous system

Acute toxicity (other routes of :

administration)

LDLo (sheep): 10 mg/kg

Application Route: Intravenous

#### oxfendazole:

Acute oral toxicity LD50 (Rat): > 6,000 mg/kg

LD50 (Dog): 1,600 mg/kg

LD50 (sheep): 250 mg/kg

#### Magnesium stearate:

Acute oral toxicity LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 423

Assessment: The substance or mixture has no acute oral tox-

icity

Remarks: Based on data from similar materials

LD50 (Rabbit): > 2,000 mg/kg Acute dermal toxicity

Remarks: Based on data from similar materials

#### Skin corrosion/irritation

Not classified based on available information.

### **Components:**

#### Oxyclozanide:

according to the OSHA Hazard Communication Standard



# Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.1 09/30/2023 7942487-00007 Date of first issue: 03/19/2021

Remarks : Not classified due to lack of data.

oxfendazole:

Species : Rabbit

Result : No skin irritation

Magnesium stearate:

Species : Rabbit

Result : No skin irritation

Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Oxyclozanide:

Remarks : Not classified due to lack of data.

oxfendazole:

Species : Rabbit

Result : No eye irritation

Magnesium stearate:

Species : Rabbit

Result : No eye irritation

Remarks : Based on data from similar materials

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

**Components:** 

Oxyclozanide:

Routes of exposure : Dermal

Remarks : Not classified due to lack of data.

Magnesium stearate:

Test Type : Maximization Test Routes of exposure : Skin contact Species : Guinea pig

Method : OECD Test Guideline 406

Result : negative

Remarks : Based on data from similar materials

according to the OSHA Hazard Communication Standard



# Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.1 09/30/2023 7942487-00007 Date of first issue: 03/19/2021

### Germ cell mutagenicity

Not classified based on available information.

#### **Components:**

Oxyclozanide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosomal aberration Test system: Human lymphocytes

Result: positive

Test Type: Mouse Lymphoma

Result: positive

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Application Route: Oral Result: negative

Test Type: unscheduled DNA synthesis assay

Species: Rat Cell type: Liver cells Application Route: Oral

Result: negative

Germ cell mutagenicity -

Assessment

Weight of evidence does not support classification as a germ

cell mutagen.

oxfendazole:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Mouse Application Route: Oral

Result: positive

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

Result: negative

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Remarks: Based on data from similar materials

according to the OSHA Hazard Communication Standard



# Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.1 09/30/2023 7942487-00007 Date of first issue: 03/19/2021

#### Carcinogenicity

Not classified based on available information.

**Components:** 

Oxyclozanide:

Remarks : Not classified due to lack of data.

oxfendazole:

Species : Rat
Application Route : Oral
Exposure time : 1 Years

Symptoms : No adverse effects.

Target Organs : Liver

Species : Rat
Application Route : Oral
Exposure time : 2 Years

Symptoms : No adverse effects.

Target Organs : Liver

IARC No ingredient of this product present at levels greater than or equal to 0.1% is

identified as probable, possible or confirmed human carcinogen by IARC.

**OSHA**No component of this product present at levels greater than or equal to 0.1% is

on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is

identified as a known or anticipated carcinogen by NTP.

#### Reproductive toxicity

May damage fertility. May damage the unborn child.

**Components:** 

Oxyclozanide:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat, male and female

Application Route: Oral

General Toxicity Parent: NOAEL: 25 - 35 mg/kg body weight Symptoms: Reduced body weight, No effects on embryofetal

and postnatal development. Result: No effects on fertility.

Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Oral

General Toxicity Parent: LOAEL: 75 - 100 mg/kg body weight Symptoms: Reduced body weight, No effects on embryofetal

and postnatal development. Result: No effects on fertility.

according to the OSHA Hazard Communication Standard



# Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.1 09/30/2023 7942487-00007 Date of first issue: 03/19/2021

Test Type: Two-generation reproduction toxicity study

Species: Rat

**Application Route: Oral** 

Early Embryonic Development: LOAEL: 75 - 100 mg/kg body

weight

Result: No fetotoxicity., No teratogenic effects.

Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Oral

General Toxicity Parent: LOAEL: 80 - 160 mg/kg body weight Result: No fetotoxicity., No teratogenic effects., No effects on

fertility

Effects on fetal development : Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 200 mg/kg body weight

Result: No fetotoxicity., No teratogenic effects.

Test Type: Development

Species: Rat

Application Route: Oral

General Toxicity Maternal: LOAEL: 100 mg/kg body weight

Result: No fetotoxicity., No teratogenic effects.

Test Type: Development

Species: Rabbit Application Route: Oral

Developmental Toxicity: NOAEL: 32 mg/kg body weight

Result: Fetotoxicity., Skeletal malformations.

Reproductive toxicity - As-

sessment

Suspected of damaging the unborn child.

oxfendazole:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat, male Application Route: Oral

Fertility: NOAEL: 17 mg/kg body weight

Target Organs: Testes Result: Effects on fertility.

Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Oral

Fertility: NOAEL: 0.9 mg/kg body weight

Target Organs: Liver

Result: No effects on fertility.

Test Type: Fertility Species: Mouse Application Route: Oral

**Duration of Single Treatment: 1 Months** 

according to the OSHA Hazard Communication Standard



# Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 09/30/2023 7942487-00007 Date of first issue: 03/19/2021 3.1

Fertility: NOAEL: 750 mg/kg body weight

**Target Organs: Testes** Result: Effects on fertility.

Effects on fetal development Test Type: Embryo-fetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 10 mg/kg body weight

Result: positive, Fetal effects.

Test Type: Embryo-fetal development

Species: Rat

Developmental Toxicity: NOAEL: 10 mg/kg body weight

Result: positive, Embryo-fetal toxicity.

Test Type: Embryo-fetal development

Species: Mouse

Application Route: Oral

Developmental Toxicity: NOAEL: 108 mg/kg body weight Result: positive, Embryo-fetal toxicity., Fetal abnormalities.

Test Type: Embryo-fetal development

Species: Rabbit Application Route: Oral

Developmental Toxicity: NOAEL: 0.625 mg/kg body weight

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of

adverse effects on development, based on animal

experiments.

Magnesium stearate:

Effects on fertility Test Type: Combined repeated dose toxicity study with the

reproduction/developmental toxicity screening test

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 422

Result: negative

Remarks: Based on data from similar materials

Test Type: Embryo-fetal development Effects on fetal development :

Species: Rat

Application Route: Ingestion

Result: negative

Remarks: Based on data from similar materials

STOT-single exposure

May cause damage to organs (Central nervous system) if swallowed.

Components:

Oxyclozanide:

Routes of exposure Oral

according to the OSHA Hazard Communication Standard



# Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.1 09/30/2023 7942487-00007 Date of first issue: 03/19/2021

Target Organs : Central nervous system
Assessment : May cause damage to organs.

#### STOT-repeated exposure

May cause damage to organs (Liver, Testis, Brain) through prolonged or repeated exposure.

#### Components:

Oxyclozanide:

Target Organs : Brain, Liver

Assessment : May cause damage to organs through prolonged or repeated

exposure.

oxfendazole:

Routes of exposure : Oral

Target Organs : Liver, Testis

Assessment : May cause damage to organs through prolonged or repeated

exposure.

#### Repeated dose toxicity

### **Components:**

### Oxyclozanide:

Species : Rat

NOAEL : 9 mg/kg

LOAEL : 44.5 mg/kg

Application Route : Oral

Exposure time : 3 Months

Target Organs : Brain, Liver, spleen, Adrenal gland

Symptoms : Liver effects

Species : Dog
NOAEL : 5 mg/kg
LOAEL : 25 mg/kg
Application Route : Oral
Exposure time : 3 Months
Target Organs : Brain, Liver

Symptoms : blood effects, alteration in liver enzymes

oxfendazole:

Species : Rat
NOAEL : 11 mg/kg
Application Route : Oral
Exposure time : 2 Weeks

Target Organs : Blood, Liver, Testis

Species : Rat

NOAEL : 3.8 mg/kg

Application Route : Oral

Exposure time : 3 Months

Target Organs : Liver, Testis

according to the OSHA Hazard Communication Standard



# Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.1 09/30/2023 7942487-00007 Date of first issue: 03/19/2021

Species : Mouse
NOAEL : 750 mg/kg
Application Route : Oral
Exposure time : 1 Months
Target Organs : Liver

Species : Mouse
NOAEL : 37.5 mg/kg
Application Route : Oral
Exposure time : 3 Months
Target Organs : Liver

Species : Dog
NOAEL : 6 mg/kg
Application Route : Oral
Exposure time : 1 Months

Remarks : No significant adverse effects were reported

Species : Dog NOAEL : 11 mg/kg Application Route : Oral Exposure time : 2 Weeks

Target Organs : Lymph nodes, thymus gland

Species : Dog NOAEL : 13.5 mg/kg

Application Route : Oral
Exposure time : 12 Months
Target Organs : Liver

Starch, oxidized:

Species : Rat

NOAEL : 22,500 mg/kg Application Route : Ingestion Exposure time : 90 Days

Magnesium stearate:

Species : Rat

NOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Remarks : Based on data from similar materials

**Aspiration toxicity** 

Not classified based on available information.

**Components:** 

Oxyclozanide:

Not applicable

according to the OSHA Hazard Communication Standard



# Oxfendazole / Oxyclozanide Formulation

Version **Revision Date:** SDS Number: Date of last issue: 04/04/2023 09/30/2023 7942487-00007 Date of first issue: 03/19/2021 3.1

**Experience with human exposure** 

Components:

Oxyclozanide:

Ingestion Symptoms: May cause, Gastrointestinal disturbance, Central

nervous system depression

**SECTION 12. ECOLOGICAL INFORMATION** 

**Ecotoxicity** 

Components:

Oxyclozanide:

aquatic invertebrates

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 0.69 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

oxfendazole:

Toxicity to fish LC50 (Lepomis macrochirus (Bluegill sunfish)): > 2.7 mg/l

Exposure time: 96 h

LC50 (Oncorhynchus mykiss (rainbow trout)): > 2.5 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0.059 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 4

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): > 4

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 0.023 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Magnesium stearate:

Toxicity to fish LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l

> Exposure time: 48 h Method: DIN 38412

Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates

EL50 (Daphnia magna (Water flea)): > 1 mg/l

Exposure time: 47 h

according to the OSHA Hazard Communication Standard



# Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.1 09/30/2023 7942487-00007 Date of first issue: 03/19/2021

Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials

No toxicity at the limit of solubility.

Toxicity to algae/aquatic

plants

EL50 (Pseudokirchneriella subcapitata (green algae)): > 1

mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

No toxicity at the limit of solubility.

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1

mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l

Exposure time: 16 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

### Persistence and degradability

**Components:** 

Oxyclozanide:

Stability in water : Hydrolysis: 50 %(156 d)

Method: OECD Test Guideline 111

oxfendazole:

Stability in water : Hydrolysis: < 5 %(4 d)

Magnesium stearate:

Biodegradability : Result: Not biodegradable

Remarks: Based on data from similar materials

**Bioaccumulative potential** 

**Components:** 

Oxyclozanide:

Partition coefficient: n- : log Pow: 3.99

octanol/water pH: 7

Method: OECD Test Guideline 107

oxfendazole:

Partition coefficient: n- : log Pow: 1.95

according to the OSHA Hazard Communication Standard



# Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.1 09/30/2023 7942487-00007 Date of first issue: 03/19/2021

octanol/water

Magnesium stearate:

Partition coefficient: n- : log Pow: > 4

octanol/water

Mobility in soil

**Components:** 

Oxyclozanide:

Distribution among environ: log Koc: 4.83

mental compartments Method: OECD Test Guideline 106

oxfendazole:

Distribution among environ-

mental compartments

log Koc: 3.2

Other adverse effects

No data available

### **SECTION 13. DISPOSAL CONSIDERATIONS**

**Disposal methods** 

Waste from residues : Dispose of in accordance with local regulations.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

#### **SECTION 14. TRANSPORT INFORMATION**

### **International Regulations**

**UNRTDG** 

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

956

(oxfendazole, oxyclozanide)

Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

**IATA-DGR** 

UN/ID No. : UN 3077

Proper shipping name : Environmentally hazardous substance, solid, n.o.s.

(oxfendazole, Oxyclozanide)

Class : 9 Packing group : III

Labels : Miscellaneous

Packing instruction (cargo

aircraft)

Packing instruction (passen: 956

18 / 22

according to the OSHA Hazard Communication Standard



# Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.1 09/30/2023 7942487-00007 Date of first issue: 03/19/2021

ger aircraft)

Environmentally hazardous : yes

**IMDG-Code** 

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(oxfendazole, Oxyclozanide)

Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### **Domestic regulation**

**49 CFR** 

UN/ID/NA number : UN 3077

Proper shipping name : Environmentally hazardous substance, solid, n.o.s.

(oxfendazole, Oxyclozanide)

Class : 9
Packing group : III
Labels : CLASS 9
ERG Code : 171

Marine pollutant : yes(oxfendazole, Oxyclozanide)

Remarks : Above applies only to containers over 119 gallons or 450

liters.

Shipment by ground under DOT is non-regulated; however it may be shipped per the applicable hazard classification to facilitate multi-modal transport involving ICAO (IATA) or IMO.

#### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

### **SECTION 15. REGULATORY INFORMATION**

#### **CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

### SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

### SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Combustible dust

Reproductive toxicity

Specific target organ toxicity (single or repeated exposure)

according to the OSHA Hazard Communication Standard



# Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.1 09/30/2023 7942487-00007 Date of first issue: 03/19/2021

SARA 313 : This material does not contain any chemical components with

known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

# **US State Regulations**

### Pennsylvania Right To Know

 Oxyclozanide
 2277-92-1

 oxfendazole
 53716-50-0

 Starch, oxidized
 65996-62-5

 Polyvinyl pyrrolidone
 9003-39-8

#### **California List of Hazardous Substances**

Polyvinyl pyrrolidone 9003-39-8

#### California Permissible Exposure Limits for Chemical Contaminants

Starch, oxidized 65996-62-5 Magnesium stearate 557-04-0

### The ingredients of this product are reported in the following inventories:

AICS : not determined


DSL : not determined

IECSC : not determined

### **SECTION 16. OTHER INFORMATION**


#### **Further information**

#### NFPA 704:



Special hazard

#### HMIS® IV:



HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

#### Full text of other abbreviations

according to the OSHA Hazard Communication Standard



# Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.1 09/30/2023 7942487-00007 Date of first issue: 03/19/2021

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

CAL PEL : California permissible exposure limits for chemical contami-

nants (Title 8, Article 107)

OSHA Z-3 : USA. Occupational Exposure Limits (OSHA) - Table Z-3 Min-

eral Dusts

ACGIH / TWA : 8-hour, time-weighted average CAL PEL / PEL : Permissible exposure limit : 8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC -International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals: OECD - Organization for Economic Co-operation and Development: OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

Data Sheet cy, http://echa.europa.eu/

Revision Date : 09/30/2023

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided

according to the OSHA Hazard Communication Standard



# Oxfendazole / Oxyclozanide Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04/04/2023

 3.1
 09/30/2023
 7942487-00007
 Date of first issue: 03/19/2021

relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8